Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: A randomized phase II trial

Annals of Oncology

Volumn 14, Issue 5, 2003, Pages 699-703

  Elomaa, Inkeri ^a   Joensuu, H ^a   Blomqvist, C ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Fluorouracil; Metastatic breast cancer; Methotrexate; Vinorelbine

Indexed keywords

ANTICONVULSIVE AGENT; CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; NAVELBINE; PROGESTERONE RECEPTOR;

ABDOMINAL PAIN; ADULT; ALOPECIA; AMNESIA; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; COLIC; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; METASTASIS; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; STOMATITIS; THROMBOCYTOPENIA; WORLD HEALTH ORGANIZATION;

EID: 0038443984     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg199     Document Type: Article

References (10)

1. Norris B, Pritchard KI, James K et al. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol 2000; 18: 2385-2394.
2. Gregory RK, Smith IE. Vinorelbine - a clinical review. Br J Cancer 2000; 82: 1907-1913.
3. Spielmann M, Zelek L. Vinorelbine. In Nabholtz J-M, Tonkin K, Aapro MS, Buzdar AU (eds): Breast Cancer Management. BCIRG, Martin Dunitz Ltd 2000; 87-97.
4. Blomqvist C, Hietanen P, Teerenhovi L, Riussanen P. Vinorelbine and epirubicin in metastatic breast cancer. A dose finding study. Eur J Cancer 1995; 31: 2406-2408.
5. Nole F, de Braud F, Aapro M et al. Phase I-II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer: A regimen with a low subjective toxic burden. Ann Oncol 1997; 8: 865-870.
6. Blajman C, Balbiani L, Block J et al. A prospective, randomized phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma. Cancer 1999; 85: 1091-1097.
7. Ejlertsen B, Mouridsen HT, Langkjer ST et al. Epirubicin and vinorelbine versus single agent epirubicin as first line chemotherapy in metastatic breast cancer. Eur J Cancer 2002; 38 (Suppl 3): 111.
8. Namer M, Soler-Michel P, Turpin F et al. Prospective randomized study comparing mitoxantrone (M) and vinorelbine (V) with fluorouracil (F), epirubicin (E) or adriamycin (A) and cyclophosphamide (C) in patients with metastatic breast cancer. Eur J Cancer 2001; 37: 1132-1140.
9. Bonneterre J, Roche H, Monnier A et al. Taxotere (TXT) versus 5-fluorouracil + navelbine (FUN) as second-line chemotherapy (CT) in patients (pts) with metastatic breast cancer (MBC) (preliminary results). Proc Am Soc Clin Oncol 1997; 16: 162a (Abstr 564).
10. Leung PP, Tannock IF, Oza AM et al. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer. J Clin Oncol 1999; 17: 3082.